Acasti Pharma Inc. (NASDAQ:ACST – Get Free Report)’s share price passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $2.75 and traded as high as $3.08. Acasti Pharma shares last traded at $2.96, with a volume of 13,180 shares trading hands.
Analyst Upgrades and Downgrades
Separately, Craig Hallum started coverage on Acasti Pharma in a report on Wednesday, February 7th. They set a “buy” rating and a $6.00 target price on the stock.
Read Our Latest Research Report on ACST
Acasti Pharma Stock Down 2.3 %
Acasti Pharma (NASDAQ:ACST – Get Free Report) last posted its quarterly earnings results on Monday, February 12th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.02. On average, analysts predict that Acasti Pharma Inc. will post -1.44 earnings per share for the current fiscal year.
Acasti Pharma Company Profile
Acasti Pharma Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.
Featured Stories
- Five stocks we like better than Acasti Pharma
- Are Penny Stocks a Good Fit for Your Portfolio?
- MarketBeat Week in Review – 4/29 – 5/3
- Learn Technical Analysis Skills to Master the Stock Market
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Following Congress Stock Trades
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.